retatrutide clinical trial results weight loss 2024 2025 press release ๐จBreaking: Retatrutide's first Phase 3 T2D data just dropped. โธ A1C: โ2.0% at 40 weeks โธ Weight: โ36.6 lbs (โ16.8%) at 12 mg โธ No plateau โ curve still descending Retatrutide is getting a lot
Description
the calculations seem wrong
With the national semaglutide injection shortage now officially resolved, FDA enforcement against mass-market compounded GLP-1 products has increased
Insights from patients: The dangers of gray market peptide sources Discussions on social media platforms reveal a mix of desperation and awareness regarding the risks of using gray market sources for compounded GLP-1 injections and other peptides
stimulated insulin release in perfused rat pancreas (Mojsov et al., 1987)
The following mechanisms explain how GLP-1 agonists improve endothelial function: 2.2.1
Compounded semaglutide contains the same active ingredient used for weight loss
